Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,140
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Pyoderma gangrenosum and Behçet’s-like disease induced by secukinumab: a paradoxical drug reaction

Ceylan Avcıa Faculty of Medicine, Department of Dermatology, Dokuz Eylul University, İzmir, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1767-4960View further author information
ORCID Icon,
Gülfem Akına Faculty of Medicine, Department of Dermatology, Dokuz Eylul University, İzmir, TurkeyORCID Iconhttps://orcid.org/0000-0001-6903-9227View further author information
ORCID Icon,
Sevgi Akarsua Faculty of Medicine, Department of Dermatology, Dokuz Eylul University, İzmir, TurkeyORCID Iconhttps://orcid.org/0000-0001-8418-2953View further author information
ORCID Icon &
Banu Lebeb Pathology Department, Dokuz Eylul University, İzmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-2520-2664View further author information
ORCID Icon
Article: 2235040 | Received 17 Mar 2023, Accepted 03 Mar 2023, Published online: 14 Jul 2023

References

  • Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:1–3. doi: 10.2147/CCID.S391356.
  • Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611. doi: 10.1111/bjd.17822.
  • Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441–e442. doi: 10.1111/jdv.17178.
  • Messina F, Piaserico S. The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. J Dermatolog Treat. 2022;33(5):2443–2454. doi: 10.1080/09546634.2022.2062281.
  • Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):999–1010. doi: 10.1111/bjd.19556.
  • Shiga H, Fukuda S, Iijima K. Interleukin-17A inhibitor-induced Crohn’s disease/Behçet’s disease-like lesions. Inflamm Bowel Dis. 2017;23(6):E38–E39. doi: 10.1097/MIB.0000000000001142.
  • Grimaux X, Leducq S, Goupille P, et al. Ulcérations buccales aphtoïdes inaugurales d’une maladie inflammatoire chronique de l’intestin induite par le sécukinumab [Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease]. Ann Dermatol Venereol. 2018;145(11):676–682. French. doi: 10.1016/j.annder.2018.07.009.
  • Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced Behçet’s syndrome: a report of two cases. Oxf Med Case Reports. 2019;31(5):omz041.
  • Barrado-Solís N, Rodrigo-Nicolás B, De la Morena-Barrio I, et al. Report of two cases of behçet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol. 2020;34(10):e587–e589. doi: 10.1111/jdv.16454.
  • Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ, et al. Behçet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges. 2021;19(1):116–118. doi: 10.1111/ddg.14196.
  • Jin K, Matsuzaki Y, Akasaka E, et al. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. 2019;46(3):e108-9–e109. doi: 10.1111/1346-8138.14611.
  • Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. Dermatol Ther. 2020;33(1):e13161.
  • Petty AJ, Whitley MJ, Balaban A, et al. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. 2020;6(8):731–733. doi: 10.1016/j.jdcr.2020.06.011.
  • Orita A, Hoshina D, Hirosaki K. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol. 2022;47(7):1372–1374. doi: 10.1111/ced.15183.
  • Weiss EH, Ko CJ, Leung TH, et al. Neutrophilic dermatoses: a clinical update. Curr Dermatol Rep. 2022;11(2):89–102. doi: 10.1007/s13671-022-00355-8.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.